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Abstract 
Background: Evidence regarding the clinical effectiveness of mite allergen avoidance for the treatment of asthma is 
lacking. In previous meta‑analyses on mite allergen control, the baseline data were not discussed in detail. This study 
updates and extends the existing Cochrane review by Gøtzsche and Johansen (Cochrane Database of Systematic 
Reviews, 2008, Art. No: CD001187), with a focus on baseline asthma outcomes and allergen exposures.
Methods: We used the existing trials in the original Cochrane review and included newly published studies. The 
baseline data for the mite allergen load from the mattress, the standardized asthma symptom score (ASS), the forced 
expiratory volume in 1 s percentage of predicted  (FEV1 %pred.), and the histamine provocative concentration causing 
a 20% drop in  FEV1  (PC20) were extracted. First, the mean values of the outcomes were calculated. The influence of the 
mite allergen load was examined with a random‑effect meta‑regression using the Metafor package in R.
Results: Forty‑five trials were included; 39 trials reported strategies for concurrent bedroom interventions, and 6 
trails reported strategies for air purification. The mite allergen load ranged from 0.44 to 24.83 μg/g dust, with a mean 
of 9.86 μg/g dust (95% CI 5.66 to 14.05 μg/g dust,  I2 = 99.8%). All health outcomes showed considerable heteroge‑
neity (standardized ASS mean: 0.13, 95% CI 0.08 to 0.18,  I2 = 99.9%;  FEV1 %pred. mean: 85.3%, 95% CI 80.5 to 90.1%, 
 I2 = 95.8%;  PC20 mean: 1.69 mg/mL, 95% CI 0.86 to 2.52 mg/mL,  I2 = 95.6%). The covariate mite allergen load did not 
significantly influence health outcomes.
Discussion: This meta‑analysis shows that mite avoidance studies are characterized by the inclusion of patients with 
rather mild to moderate asthma and with varying and sometimes negligible levels of allergen exposure. Future stud‑
ies should focus on patients with severe asthma and increased levels of allergen exposure.
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is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
House dust mite-allergic asthma is a prevalent disorder 
of the lower airways that affects hundreds of millions of 
people worldwide [1, 2]. The immediate allergic reac-
tion to mites [3] suggests that controlling exposure to 
the antigen could be an appropriate first-line therapy for 
the treatment of mite-allergic asthma. However, guide-
lines and reviews provide ambiguous recommendations 
for mite allergen avoidance [4–6], reflecting a lack of 
consensus in this research field. This lack of consensus 
on the effectiveness of mite allergen avoidance is sum-
marized by a Cochrane review [7], which was unable to 
demonstrate any clinical benefit of avoidance measures 
designed to reduce mite exposure in 55 trials. In addi-
tion to the substantial meta-analysis by Gøtzsche and 
Johansen [7], several other meta-analyses on mite aller-
gen avoidance for the treatment of asthma report vary-
ing results for the effectiveness of avoidance [8–11]. The 
variation in the complex interventions as well as the het-
erogeneity of several study outcomes urges further explo-
ration [12, 13].
The baseline data are a not well reported in the meta-
analyses on the effectiveness of mite allergen control. 
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These baseline characteristics provide attributes for 
evidence-based decision making in the daily practice of 
clinicians [14]. First, in the case of asthma, baseline char-
acteristics are of particular interest because they reflect 
the level of asthma control and the asthma severity of 
the patient [15]. Studies still highlight the disparities 
between the asthma severity results between clinical tri-
als and those reported from patient practice [16]. Treat-
able traits have been defined in severe asthma patients 
and may be associated with future exacerbation risk [17]. 
Second, baseline environmental aspects can influence the 
treatability of allergen-induced asthma [18]. Third, base-
line characteristics provide statistical independence in 
the asthma outcomes of interest. This quantitative factor 
relates to the possible relationship between exposure and 
asthma outcomes; for example, in the paradigm of the 
bedding site introduced in the 1990s [19]. In such cases, 
the quantitative evaluation of the clinical effectiveness of 
the treatment of asthma in a meta-analysis differs from 
that of the traditional two-sample test [20]. These aspects 
demonstrate that baseline characteristics in a meta-
analysis are important for the interpretation of the study 
results [21].
This study updates and extends the existing Cochrane 
review by Gøtzsche and Johansen [7], with a focus on 
baseline asthma outcomes and allergen exposures.
Methods
Searches and selections
The starting point for this protocol was the Cochrane 
review by Gøtzsche and Johansen [7]. This meta-analysis 
includes 55 trials. An updating search was performed 
in the EMBASE, Medline, and Cochrane databases 
(see Additional file  1: Appendix S1). The titles and/or 
abstracts of the retrieved updated studies were screened 
in Endnote by the first author to identify randomized tri-
als that met the inclusion criteria. Searches and selections 
were checked by a second author (NWJ). We selected all 
trials by applying the following inclusion criteria; where 
possible, criteria derived from Gøtzsche and Johansen [7] 
was applied.
• The study was published in the English language.
• The study was a peer-review publication with full text 
(no abstracts).
• The study was a randomized controlled trial with 
blinding.
• The control included a placebo or no treatment (by 
Gøtzsche and Johansen [7]).
• The participants were physician-diagnosed with 
bronchial allergic asthma. These included partici-
pants who underwent a mite sensitization assess-
ment with either a skin test or serum assay for spe-
cific IgE antibodies (by Gøtzsche and Johansen [7]). 
The asthma assessment included a history of asthma 
symptoms and a pulmonary function test.
• The intervention was designed to reduce the expo-
sure to mite antigens in the home for the treatment 
of asthma (mono-trigger therapy by tertiary avoid-
ance). This could include one of the following (by 
Gøtzsche and Johansen [7]):
a. Chemical (acaricides);
b. Physical (mattress covers, vacuum-cleaning, 
heating, ventilation, freezing, washing, air-filtra-
tion, and ionisers);
c. A combination of chemical and physical.
The flow chart of the updating search was made by use 
of the PRISMA diagram [22].
Data extraction
The data extraction was elaborated by the first author 
(FvB); the extracted data included the study popula-
tion, the type of intervention and control (the strategy of 
avoidance [13]), the study methodology (randomization 
and blinding), and outcomes. The outcomes included the 
main outcomes and the additional outcomes.
Main outcomes
• Mite allergen load from the mattress (μg/g dust).
• Asthma symptom score diaries (e.g. ASS/ACQ).
• Forced expiratory volume in 1  s percentage of pre-
dicted (%)  (FEV1 %pred.)
• Histamine or methacholine concentration that 
causes a 20% reduction in the  FEV1  (PC20).
Additional outcomes
• Medication usage (use of inhaled corticosteroids: yes 
or no).
• Type of patient (child or adult).
• Presence of co-sensitization.
Missing data were requested from the study authors. 
A second author (NWJ) validated the selections and 
the data extraction by the first author. Any ambiguities 
in the selections and the extractions were resolved by 
discussion.
The mite allergen load in trials was measured by the 
allergen content, the number of mites or the guanine 
content. A rapid colorimetric test such as the  Acarex® 
test can be used to measure the latter. Mite allergen 
exposure measured by  Acarex® or an equivalent test was 
Page 3 of 12van Boven et al. Clin Transl Allergy            (2020) 10:2 
excluded from the analysis; the  Acarex® test is poorly 
correlated with allergen content [23]. To estimate the 
allergen load from the number of mites in mattresses, 
the mean number of mites can be divided by a factor of 
50. This ratio is adapted from a nonsensitization thresh-
old for allergens and for mites [24]. However, confidence 
limits for this calculation are unknown. We therefore also 
excluded mite counts. The most reliable way to meas-
ure the allergen content is with a chemical assay; the 
Enzyme-Linked Immuno Sorbent Assay (ELISA). In an 
ELISA the house dust mite allergens in the dust extract 
binds to an antibody, and are consequently linked to an 
enzyme, producing a detectable signal correlating to the 
antigen concentration in the extract [25]. This assay has 
been the most acceptable assay since 1989 [26]. We lim-
ited the studies to those measuring the mass (μg/g dust) 
of the mite allergen loads in mattresses with ELISA. Early 
epidemiologic studies defined a threshold level of 10.0 μg 
mite allergen per gram of dust, above which asthmatic 
patients are in risk of asthma attacks [24]. Confidence 
boundaries were absent, reducing the threshold to a rule 
of thumb. Since then, there is a lack of papers on this 
threshold level, and thus never updated.
Questionnaires have been developed to measure 
asthma symptom scores and the adequacy of asthma 
control, regarding shortness of breath, wheeze, woken by 
asthma, severity of asthma in the morning, limiting activ-
ities because of asthma, use of a short-acting bronchodi-
lator [27]. A limitation of the ASSs is that are no validated 
cut-off points indicating severity or level of control. In 
the validated questionnaire by Juniper, an ACQ of 1.50 
(maximum 6) relates to inadequately controlled asthma, 
[28], corresponding to a standardized cut-point of 0.25. 
The  FEV1 measures the obstruction in the airways dur-
ing a forced expiratory flower using a spirometer [15]. 
An  FEV1 %pred. of 50 to 79% refers to moderate airflow 
obstruction, and < 50% to (very) severe obstruction [29]. 
In a standardized bronchoprovocation test, the dose his-
tamine or methacholine is determined causing a 20% fall 
in  FEV1,  PC20 or  PD20 [30]. A  PC20 < 1 mg/mL is consid-
ered a severe airway hyper responsiveness, and > 8  mg/
mL as being a normal responsiveness [31].
The analysis was limited to the main health outcomes 
with the most reported units. In the case of the ASS, we a 
priori standardized (SMN) the mean (MN) score by divid-
ing it by the maximum number of the score (MAX). The 
variance was standardized in the same way (SD2standardized 
= SD2extracted/(MAX2 * number of patients)).
Risk of bias assessment
Gøtzsche and Johansen [7] judged the adequacy of the 
allocation concealment according to the Cochrane 
guidelines [32]. Their assessment was not included in 
the data synthesis. The trials selected for the updated 
analysis were assessed similarly for the risk of bias by 
the first author (FvB) using the Cochrane checklist [32]. 
A second author (NWJ) validated the assessment by the 
first author. Any ambiguities in the assessed risk of bias 
were resolved by discussion. We also did not include the 
assessments in the data synthesis, as we did not hypoth-
esize that the risk of bias or the quality of trials would 
affect the baseline characteristics.
Statistical and sensitivity analyses
The effect size was set as the mean for the physiological 
outcomes. The ASSs were standardized. First, the over-
all effect of the three health outcomes was estimated 
using a random-effects meta-analysis. Additionally, the  I2 
value was calculated to examine heterogeneity in the out-
comes. A random-effect meta-regression and subgroups 
were introduced for all medical outcomes showing at 
least moderate heterogeneity. Covariates and subgroups 
of interest included the mite allergen load from the mat-
tress at baseline and possible confounding by the use of 
inhaled corticosteroids, the type of patient (child/adult), 
and the presence of co-sensitization. Random-effects 
meta-regressions and subgroups were tested for a pre-
ferred minimum of ten trials [32]. Another sensitivity 
analysis yielded the exclusion of possible outliers as well 
as the results of the updated reference search. All calcu-
lations were performed with the Metafor 2.0.0 package 
in R 3.5.3. [33, 34]. The level of significance was set to 
α = 0.05.
Results
Selection of references
The selection and inclusion of studies resulted in two 
groups of publications. The first group included the tri-
als from the Gøtzsche and Johansen [7] analysis (fifty-five 
trials published until July 2011 [35–89]). We excluded 
twelve of these trials for being only abstracts, being pub-
lished in a non-English language, not reporting data on 
the treatment of mite-allergic asthma, or containing 
non-usable data (outcomes not of prior interest; incom-
plete data) [35–45, 87]. One of the excluded trials was a 
large trial by Woodcock et al. [87], which dominated the 
meta-analysis by Gøtzsche and Johansen (weight > 40%). 
Woodcock et  al. [87] reported incomplete data in the 
subset of the mite load as well as the ASS. Further, the 
research team did not report the  FEV1 or the  PC20 data. 
The remaining forty-three trials were included for data 
extraction. The second group included studies identified 
in our updated search starting in July 2011 (Fig.  1). We 
found a total of 942 titles and abstracts. Nine hundred 
and fifteen titles were excluded for not reporting a rand-
omized blinded trial on the effectiveness of tertiary mite 
Page 4 of 12van Boven et al. Clin Transl Allergy            (2020) 10:2 
allergen avoidance. Twenty-eight potentially relevant 
titles were selected for inclusion [90–117]. Twenty-six 
full-text articles were excluded for not meeting our inclu-
sion criteria (see Additional file  1: Appendix S1). Two 
full-text articles were included in the analysis [97, 115]. 
Finally, forty-five full-text articles were included in the 
analysis.
Description of the included trials
Thirty-nine trials reported avoidance using concur-
rent bedroom intervention strategies, and six trials 
reported air purification strategies. In twenty-five trials 
(56%), patients used inhaled corticosteroids at baseline. 
Twenty-one trials reported on the treatment of children 
with allergic asthma, the other twenty-four reported on 
the treatment of adults; some trials included both chil-
dren and adults. In nineteen trials, co-sensitization at 
baseline was reported. Gøtzsche and Johansen [7] pre-
viously reported that eight of the included trials had a 
low risk of bias. Seven trials were judged to have a high 
risk of bias. The bias in the remaining twenty-eight tri-
als was deemed unclear by Gøtzsche and Johansen [7]. 
We judged the trial by El-Ghitany and El-Salam [97] to 
have an unclear risk of bias (no information on conceal-
ment was included). The trial by Murray et al. [115] was 
judged to have a low risk of bias (use of a computer-
based minimization procedure).
Records idenfied through 
database searching
(n =  942 )
Addional records idenfied 
through other sources
(n =  0 )
Records aer duplicates removed
(n =  942 )
Records screened
(n =  942 )
Records excluded
(n =  915 )
Full-text arcles assessed 
for eligibility
(n =  28 )
Full-text arcles excluded;
- only abstract (n=4)
- duplicate (n=4)
- not terary 
prevenon (n=3)
- not a RCT (n=9)
- not paents with 
mite allergic 
asthma (n=4)
- protocol issue
(n=2) 
Studies included in 
quantave synthesis 
(meta-analysis)
(n =  2 )
Fig. 1 Flow chart of the updating literature search and selection of studies
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Mean characteristics at baseline
Seventeen of the forty-five trials reported on the mite 
allergen load from the mattress at baseline, as measured 
by ELISA (mean 9.86 μg/g dust; 95% CI 5.66 to 14.05 μg/g 
dust; range 0.44 to 24.83 μg/g dust; n = 1066;  I2 = 99.8%; 
Fig. 2). The standardized ASSs at baseline were reported 
in twelve trials with high heterogeneity (standardized 
symptom score = 0.13; 95% CI 0.08 to 0.18; range: 0.03 to 
0.29; n = 703;  I2 = 99.9%; Fig. 3). Sixteen studies reported 
the outcome  FEV1  %pred. by measuring the percentage 
predicted value  (FEV1  %pred. = 85.3%; 95% CI 80.5 to 
90.1%; range 68.5 to 102.2%; n = 816;  I2 = 95.8%; Fig.  4). 
Fifteen trials reported  PC20 values at baseline, expressed 
as mg/mL. The mean  PC20 was 1.69 mg/mL (95% CI 0.86 
to 2.52 mg/mL; n = 599;  I2 = 95.6%, Fig. 5).
Dependence, subgroups and sensitivity analysis
The covariate mite allergen load at baseline did not sig-
nificantly influence the health outcomes (standardized 
ASSs: P = 0.13;  FEV1  %pred.: P = 0.81;  PC20: P = 0.75, 
see Additional file  1: Appendix S1). We calculated 
the  FEV1  %pred. in the adult subgroup  (FEV1  %pred.; 
adults = 84.2%, 95% CI 79.2 to 89.2%; 11 trials). All other 
subgroups included less than ten trials. Finally, the ran-
dom-effects models for the health outcomes were unal-
tered when excluding the updated trials (symptom score 
0.12;  FEV1 %pred.: 85.4%;  PC20: 1.69 mg/mL).
Discussion
This study contributes to the existing Cochrane review 
by Gøtzsche and Johansen [7] by generating hypotheses 
on the characteristics of asthma outcomes according to 
baseline data as well as possible dependencies for asthma 
outcomes. We observed considerable heterogeneity in 
the mite allergen load in the mattresses (17 trials), the 
standardized ASSs (12 trials), the  FEV1  %pred. values 
(16 trials), and the  PC20 values (15 trials). We judged 
Fig. 2 Forest plot of the mite allergen load of the mattress at baseline
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the mean mite allergen load from the mattress at base-
line to be moderate (9.86 μg/g dust). Overall, the stand-
ardized ASSs and the percentage predicted  FEV1 %pred. 
suggested a mild to moderate disease. The  PC20 at base-
line predominantly indicated moderate to severe air-
way hyperresponsiveness according to the definition by 
Cockroft [31]. We did not observe a relationship between 
the mite allergen load from the mattress at baseline and 
health outcomes. The number of trials available did not 
allow for comparisons between the child and adult sub-
groups, the inhaled corticosteroid use or no use sub-
groups, or the presence or absence of co-sensitization 
subgroups.
In this study, we observed several factors related to the 
three attributes of prior interest. The first attribute was 
asthma severity. We observed a mild to moderate mag-
nitude of asthma severity at baseline. We were, how-
ever, limited in our evaluation of asthma severity by the 
absence of appropriate instruments to assess asthma 
control [27, 118] and the asthma-related quality of life 
[119]. Compatible with the situation of pharmacological 
treatments [16], it remains unknown whether the results 
found by Gøtzsche and Johansen [7] are generalizable to 
patients with uncontrolled asthma. In one trial [55], we 
extracted a median symptom score at daytime of zero 
for the treatment group. Since the score was already zero 
at baseline, it was probably clear that there would be no 
clinical benefit observed in this subset. The asthma out-
comes showed more notable levels, such as a  FEV1 %pred. 
above 100%, as reported by Carswell et al. [51]. The mod-
erate asthma status at baseline was possibly related to the 
use of inhaled corticosteroids, as reported in more than 
half of the included trials (56%). However, the number of 
trials available did not allow for testing this hypothesis.
A second attribute is the magnitude of the expo-
sure at baseline, which relates to the environmental 
treatability. In four of the included trials [51–53, 115], 
we observed that the mean mite allergen load from 
the mattress at baseline was quite low (range 0.44 to 
1.91  μg/g dust). Only one of these four trials included 
Fig. 3 Forest plot of the standardized asthma symptom scores at baseline
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an evaluation of the treatability of mite allergen expo-
sure at baseline in their methods [52]. Environmentally, 
whether such low values of exposure are considered 
treatable remains a question. An exposure level of 
0.44  μg/g dust is quite similar to the exposure level 
observed in the “low-allergen” region of Davos in the 
European Alps (approximately 0.02 to 0.2  μg/g dust; 
assessed from [120]). In addition, Pingitore and Pinter 
[121] noted that in many trials, there was no success in 
reducing the mite allergen load. Overall, it seems that 
multiple clinical trials on avoidance paid little atten-
tion to the environmental issue of the treatability of the 
exposure.
Furthermore, the attribute of dependence was of inter-
est in this study. None of the medical baseline data could 
be related to mite allergen exposure from the mattress. 
This indicates that from a meta-viewpoint, at baseline, 
there was no clinical potential for reducing the mite aller-
gen load in the bedding.
As far as we know, this is the first systematic review 
of baseline characteristics in trials on mite allergen 
avoidance for the treatment of asthma. This study was 
executed a priori to generate hypotheses for a new meta-
analysis on the treatment of mite-allergic asthma by 
environmental control. Generating hypotheses to define 
a protocol for a meta-analysis prevents misleading con-
clusions [32]. We could not generate a hypothesis on a 
possible relationship with asthma outcomes, particularly 
considering the mite allergen exposure covariate. The 
mite allergen load from the mattress covariate was lim-
ited to the data obtained from ELISA. This limitation 
can be considered a rigorous selection factor to prevent 
bias in this covariate of prior interest. It is possible that 
some of the covariates we used were still unrefined. For 
instance, the covariate co-sensitization was introduced as 
a binary value (presence yes or no); we believe the next 
step is to introduce the number of co-sensitizations as an 
ordinal covariate.
Fig. 4 Forest plot of the  FEV1 percentage of predicted at baseline
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The main limitation of this study was that we had to 
exclude the large trial by Woodcock et  al. [87] because 
their data was not usable data for the purpose of this 
study. Woodcock et al. did probably not include patients 
with uncontrolled asthma. Their publication included 
only adult patients with asthma who were undergo-
ing routine management with inhaled corticosteroids 
in primary care. Though not a limitation, another large 
trial also worth noting is the recently published study 
by Murray et al. [115]. Murray et al. found that only the 
use of single covers prevented asthma exacerbations in 
the hospital setting. In a post hoc analysis, Murray et al. 
reported that relatively younger children (P = 0.006), 
those mono-sensitized to mites (P = 0.04), those with 
severe asthma (P = 0.03), and those not exposed to smok-
ing (P = 0.02) explained the reduced number of hospital 
admissions in the 123 participants. No information was 
presented on the selection of significant covariates or 
on the power of the calculations. Possibly, the results by 
Murray et al. [115] are explained by a more severe asthma 
status at baseline than those in the participants in the tri-
als included by Gøtzsche and Johansen [7].
The baseline characteristics in a meta-analysis have 
been the subject of methodological studies, emphasiz-
ing the careful consideration of this topic in the defi-
nition of the protocol [21, 122]. Advanced statistical 
methods to evaluate underlying risk have been devel-
oped for cases in which the baseline characteristics or 
the severity of the disease among the participants varies 
[123]. The definition of the types of participants is con-
sidered a key factor in reviews [32]. A positive example 
of the explicit (a priori) consideration of baseline char-
acteristics was demonstrated in the Cochrane review 
on the treatment of asthma by sublingual immunother-
apy [124]. In contrast, the current meta-analyses on the 
treatment of asthma using avoidance were commonly 
characterized by no baseline characteristic reporting 
[7–11]. Gøtzsche and Johansen [7] stated that adjusting 
Fig. 5 Forest plot of the  PC20 at baseline
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for baseline differences would risk biasing the review, 
“since investigators are inclined to show baseline dif-
ferences and adjust for them when this procedure 
favours the experimental treatment”. By limiting their 
meta-analysis to the changes and final values, Gøtzsche 
and Johansen [7] did not account for the types of par-
ticipants they reviewed. Other Cochrane reviews on the 
treatment of asthma or rhinitis by mite allergen avoid-
ance [125, 126], recognized for their rigorous method-
ology, do not account for the types of participants, as 
they did not describe their baseline characteristics. This 
suggests that there is room for improvement in the 
multiple Cochrane reviews and other meta-analyses on 
avoidance.
In conclusion, this systematic review demonstrates 
that many previous mite avoidance studies are charac-
terized by the inclusion of patients with rather mild to 
moderate asthma and with varying and sometimes neg-
ligible levels of allergen exposure. Most likely, the use of 
asthma medication modified the baseline asthma out-
comes in these studies, leaving less room to improve. 
In future studies, we suggest focusing on patients with 
partially controlled or uncontrolled asthma and assess-
ing asthma control with the appropriate instruments 
[27, 118, 119]. Moreover, to test the efficacy of allergen 
avoidance, sufficient mite exposure at baseline should 
be present. In the absence of an evidence-based thresh-
old level, we suggest the provisional use of the formerly 
defined rule of thumb that suggests that 10.0  μg mite 
allergen per gram of dust is relevant to asthma symp-
toms [19].
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